» Articles » PMID: 38182756

Single-cell Analysis Reveals the Stromal Dynamics and Tumor-specific Characteristics in the Microenvironment of Ovarian Cancer

Overview
Journal Commun Biol
Specialty Biology
Date 2024 Jan 5
PMID 38182756
Authors
Affiliations
Soon will be listed here.
Abstract

High-grade serous ovarian carcinoma (HGSOC) is a heterogeneous disease, and a highstromal/desmoplastic tumor microenvironment (TME) is associated with a poor outcome. Stromal cell subtypes, including fibroblasts, myofibroblasts, and cancer-associated mesenchymal stem cells, establish a complex network of paracrine signaling pathways with tumor-infiltrating immune cells that drive effector cell tumor immune exclusion and inhibit the antitumor immune response. In this work, we integrate single-cell transcriptomics of the HGSOC TME from public and in-house datasets (n = 20) and stratify tumors based upon high vs. low stromal cell content. Although our cohort size is small, our analyses suggest a distinct transcriptomic landscape for immune and non-immune cells in high-stromal vs. low-stromal tumors. High-stromal tumors have a lower fraction of certain T cells, natural killer (NK) cells, and macrophages, and increased expression of CXCL12 in epithelial cancer cells and cancer-associated mesenchymal stem cells (CA-MSCs). Analysis of cell-cell communication indicate that epithelial cancer cells and CA-MSCs secrete CXCL12 that interacte with the CXCR4 receptor, which is overexpressed on NK and CD8+ T cells. Dual IHC staining show that tumor infiltrating CD8 T cells localize in proximity of CXCL12+ tumor area. Moreover, CXCL12 and/or CXCR4 antibodies confirm the immunosuppressive role of CXCL12-CXCR4 in high-stromal tumors.

Citing Articles

Subtype-specific analysis of gene co-expression networks and immune cell profiling reveals high grade serous ovarian cancer subtype linkage to variable immune microenvironment.

Carey K, Young C, Clark A, Dammer E, Singh R, Lillard Jr J J Ovarian Res. 2024; 17(1):240.

PMID: 39627836 PMC: 11613732. DOI: 10.1186/s13048-024-01556-4.


Effect of fibroblast heterogeneity on prognosis and drug resistance in high-grade serous ovarian cancer.

Wang T, Tian L, Wei B, Li J, Zhang C, Long R Sci Rep. 2024; 14(1):26617.

PMID: 39496775 PMC: 11535537. DOI: 10.1038/s41598-024-77630-0.


Egfl6 promotes ovarian cancer progression by enhancing the immunosuppressive functions of tumor-associated myeloid cells.

Hamze Sinno S, Imperatore J, Bai S, Gomes-Jourdan N, Mafarachisi N, Coronnello C J Clin Invest. 2024; 134(21).

PMID: 39312740 PMC: 11527450. DOI: 10.1172/JCI175147.


Stromal cartilage oligomeric matrix protein as a tumorigenic driver in ovarian cancer via Notch3 signaling and epithelial-to-mesenchymal transition.

Gorji-Bahri G, Krishna B, Hagerling C, Orimo A, Jirstrom K, Papadakos K J Transl Med. 2024; 22(1):351.

PMID: 38615020 PMC: 11016227. DOI: 10.1186/s12967-024-05083-0.

References
1.
Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

2.
Steg A, Katre A, Bevis K, Ziebarth A, Dobbin Z, Shah M . Smoothened antagonists reverse taxane resistance in ovarian cancer. Mol Cancer Ther. 2012; 11(7):1587-97. PMC: 3392529. DOI: 10.1158/1535-7163.MCT-11-1058. View

3.
Stahl P, Salmen F, Vickovic S, Lundmark A, Fernandez Navarro J, Magnusson J . Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. Science. 2016; 353(6294):78-82. DOI: 10.1126/science.aaf2403. View

4.
. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15. PMC: 3163504. DOI: 10.1038/nature10166. View

5.
Xu J, Fang Y, Chen K, Li S, Tang S, Ren Y . Single-Cell RNA Sequencing Reveals the Tissue Architecture in Human High-Grade Serous Ovarian Cancer. Clin Cancer Res. 2022; 28(16):3590-3602. PMC: 9662915. DOI: 10.1158/1078-0432.CCR-22-0296. View